Catalyst Dossier · compiled by CeliA 🧫

Replimune Group, Inc. (REPL)

Biological Products, (No Diagnostic Substances) · market cap $841M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10
2027-01-01 (est.)Phase 2 · RP2imp 7/10
2027-05-24 (est.)PDUFA · RP1imp 8/10

Pipeline

Asset	Phase	Indication
RP3	Phase 2	Refractory Metastatic Colorectal Cancer
RP2 Monotherapy	Phase 2	Hepatocellular Carcinoma
RP1	Phase 2	Non-Small Cell Lung Cancer (NSCLC)
Vusolimogene Oderparepvec	Phase 3	Advanced Melanoma
Cemiplimab	Phase 2	Cutaneous Squamous Cell Carcinoma
RP2	Phase 3	Metastatic Uveal Melanoma
RP1, intra-tumoral injection, oncolytic virus	Phase 2	Cutaneous Squamous Cell Carcinoma

Price & technical context

3-month

+52.2%

6-month

+17.9%

12-month

+26.6%

52-wk range

$1.70–$12.63

vs 50-day MA

+70.8%

vs 200-day MA

+58.7%

Realized vol

246.6%

Max drawdown

-88.6%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for REPL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.